U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07946120) titled 'Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab' on Nov. 13.
Brief Summary: Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if <1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra(R)), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.
Since 2018 (and 2023 for moderate hemophilia A), subc...